$150 Million

Relypsa

Follow-on Offering

Bookrunner, February 2015

Operator of a biopharmaceutical company. The company is focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are overlooked and under treated and can be addressed in the gastrointestinal tract.